Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2000 Oct;131(4):655-8.
doi: 10.1038/sj.bjp.0703646.

Neuroprotection against hypoxic/hypoglycaemic injury after the insult by the group III metabotropic glutamate receptor agonist (R, S)-4-phosphonophenylglycine

Affiliations

Neuroprotection against hypoxic/hypoglycaemic injury after the insult by the group III metabotropic glutamate receptor agonist (R, S)-4-phosphonophenylglycine

C F Sabelhaus et al. Br J Pharmacol. 2000 Oct.

Abstract

The role of group III metabotropic glutamate receptors (mGluR) in ischaemic neurodegeneration is still unsettled. In order to examine a possible modulatory effect of these receptors on ischaemia-induced damage we tested the novel selective agonist (R, S)-4-phosphonophenylglycine [(R,S)-PPG] after an hypoxic/hypoglycaemic insult in rat hippocampal slices. The recovery of population spike amplitudes in the CA1-region was used as parameter for neuronal viability. (R,S)-PPG significantly improved the recovery of synaptic transmission in the CA1-region even when applied only during the recovery period. The results imply that presynaptic glutamate release after an insult contributes to neurodegeneration. Since agonists of group III mGluR reduce neurotransmitter release - probably via presynaptic autoreceptors - we interpret the results obtained in our in vitro model of hypoxia/hypoglycaemia as support of the hypothesis that group III mGluR agonists might be beneficial drugs against diseases where excitotoxicity is one of the dominant pathological mechanisms.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Effect of the novel selective group III agonist (R,S)-4-phosphonophenylglycine ((R,S)-PPG, 30 μM) on the recovery of PS in area CA1 of rat hippocampal slices after a 4 min hypoxia/hypoglycaemia. (a) The representative traces show evoked PS recorded immediately before, during and at different time points after hypoxia/hypoglycaemia. In the second column (R,S)-PPG was present from the time of re-establishment of oxygen and glucose supply for throughout the recovery period. (b) Time course of PS recovery in untreated control slices (n=6) and in slices treated with 30 μM (R,S)-PPG (n=6). Asterisks indicate significant differences from control slices, calculated with Mann-Whitney's U-test (*P<0.05; **P<0.01). Data are expressed as the mean±standard error.

Similar articles

Cited by

References

    1. ABDUL-GHANI A., ATTWELL P.J.E., SING KENT N., BRADFORD H.F., CROUCHER M.J., JANE D.E. Anti-epileptogenic and anticonvulsant activity of L-2-amino-4-phosphonobutyrate, a presynaptic glutamate receptor agonist. Brain Res. 1997;755:202–212. - PubMed
    1. BIGGE C.F., DRUMMOND J.T., JOHNSON G., MALONE T., PROBERT A.W., JR, MARCOUX F.W., COUGHENOUR L.L., BRABES L.J. Exploration of phenyl-spaced 2-amino-(5-9)-phosphonoalkanoic acids as competitive N-methyl-D-aspartatic acid antagonists. J. Med. Chem. 1989;32:1580–1590. - PubMed
    1. BOND A., O'NEILL M.J., HICKS C.A., MONN J.A., LODGE D. Neuroprotective effects of a systemically active group II metabotropic glutamate receptor agonist LY354740 in a gerbil model of global ischaemia. NeuroReport. 1998;9:1191–1193. - PubMed
    1. BRADLEY S.R., LEVEY A.I., HERSCH S.M., CONN P.J. Immunocytochemical localization of group III metabotropic glutamate receptors in the hippocampus with subtype specific antibodies. J. Neurosci. 1996;16:2044–2056. - PMC - PubMed
    1. BRUNO V., BATTAGLIA G., KINGSTON A., O'NEILL M.J., CATANIA M.V., DI GREZIA R., NICOLETTI F. Neuroprotective activity of the potent and selective mGlu1a metabotropic glutamate receptor antagonist, (+)-2-methyl-4-carboxyphenylglycine (LY367385): comparison with LY357366, a broader spectrum antagonist with equal affinity for mGlu1a and mGlu5 receptors. Neuropharmacology. 1999;38:199–207. - PubMed

Publication types

LinkOut - more resources